Gov. DeWine orders Ohio Board of Pharmacy to ban synthetic kratom immediately - The Statehouse News Bureau
Ohio Governor DeWine orders the Ohio Board of Pharmacy to immediately ban synthetic kratom, affecting all pharmacies and dispensaries in the state.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All Ohio pharmacies, including independent, retail chain, compounding, and long-term-care pharmacies, as well as any entity dispensing or selling synthetic kratom. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate; no grace period.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Synthetic kratom is now banned in Ohio; possession, sale, or dispensing is prohibited immediately.
Who it affects
All Ohio pharmacies, including independent, retail chain, compounding, and long-term-care pharmacies, as well as any entity dispensing or selling synthetic kratom.
What you must do
Remove all synthetic kratom products from inventory and cease any dispensing or sales immediately.
Deadline
Immediate; no grace period.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order